NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether STAAR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 11, 2025, STAAR issued a press release reporting its financial results for the fourth quarter and full year 2024. Among other items, for the quarter, STAAR reported GAAP earnings per share of -$0.69, missing consensus estimates by $0.55, and revenue of $48.95 million, missing consensus estimates by $28.52 million. The Company attributed its results to "fluctuating demand in China".
On this news, STAAR’s stock price fell $5.40 per share, or 24.68%, to close at $16.48 per share on February 12, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
COMTEX_463054733/2457/2025-02-23T10:08:14